Allianzim US Large Cap Buffer10 May ETF (MAYT) ニュース

I disagree. Stopping a potential competitor like Alteogen in its tracks would benefit Halozyme immensely, IMHO.

lol....no. It doesn't work like that.

https://www.merriam-webster.com/dictionary/support

I certainly do not have a problem with the pick because it is not something that needs to be solved. Therefor, it is not a problem.

your hubris and hatred for Franky, blinds you of the value of saving human lives, around 50% of many dispensaries have gray or counterfeit produfts.  you will be judged by the all mighty.  

I thought you'd like this: https://www.ccn.com/news/business/gold-prices-rise-discovery-china-new-record-ahead/

This rally is off the charts, as far as I can see it's pure Fundamentals now ...charts are in the rear view mirror

Decease and desist that you referred to in your message, would not benefit Halozyme. Halo  would much rather have either a license fee or some penalty for infringement. The only real entity that would benefit from a C and desist would be brystol Myers, in which case they would be back in Halozyme wi

Share Structure - Updated November 23, 2024

Transfer Agent Verified

No change - no dilution

Authorized Shares: 2,400,000,000

Outstanding Shares: 2,115,876,871

Restricted: 186,002,437

Unrestricted: 1,929,874,434

Thank you for posting this.

-- OJ

To your point, though, it is possible that BMY might be willing to chip in to the HALO legal fund in order to slow or otherwise hamper SC Keytruda's entry into the marketplace, thus strengthening HALO's hand.

I never said it did. And i was replying to Hawks regarding the quote and link coming from some TV guy...which OZ became. As in the guy is just jealous of Oz's carreer. Which is obviously is..lol.

India? Why no news in the US? I think I know why.

Share Structure - Updated November 18, 2024:

Transfer Agent Verified

No change - no dilution

Authorized Shares: 12,000,000,000

Outstanding Shares: 3,142,243,272

Restricted: 383,572,035

Unrestricted: 2,758,671,2

2025 is shaping up to be a good year. I am in several tickers that seem set to explode in the next 12 months or so.

Gotta be tuff pretending to others this is still a winner when clearly it's a loser.


SEC DELINQUENT NOTICE ON ASII

I chat with "the bot" on the phone several times a week...but carry on Mr. Sunshine.

25 November 2024
Successfulsoil program develops new targets at the
West Wodgina Lithium Project
Highlights
https://clients3.weblink.com.au/pdf/SYA/02884949.pdf
5 targets identified with Li2O assays up to 255ppm from successful soil sampling program
New tar

Share Structure - Updated November 23, 2024

Transfer Agent Verified

Authorized Shares: 3,000,000,000

Outstanding Shares: 13,224,737

- Restricted: 8,269,251

- Unrestricted: 4,955,486

25 November 2024
Successfulsoil program develops new targets at the
West Wodgina Lithium Project
Highlights
https://clients3.weblink.com.au/pdf/SYA/02884949.pdf
5 targets identified with Li2O assays up to 255ppm from successful soil sampling program
New tar

Lot YGF1 is ready for harvest

Tomorrow will be the beginning of YUGE MASSIVE move for share price.

What is hard to understand is why someone spends so much time bashing a company

Hoskuld is not an AVXL basher in my opinion as I believe his criticisms are valid and can be backed up by facts. If you think Hoskuld bashes AVXL, I can't imagine how I am supposed to feel about his comm

The bot is AI, has no shares. Sorry fella . Find a real hero

You are assuming that HALO's only recourse is to ask for a cut of the royalties. One might assume HALO could, in the alternative, gain a cease-and-desist order before SC Keytruda ever makes it to market. Thus, Merck has skin in the game, and they are not going to be passively watching from the sidel

So much talk about what Misleading coulda, woulda, shoulda done. Misleading is an arrogant buffoon who will never learn his lesson. Any other company would have course-corrected after the Avatar failure, but he did nothing for Excellence and now has designed one of the tiniest trials for 3-71. "The